Companies - Pharming

Price

 
Price
€ 0,92
Change
€ -0,02
Change %
-2,65%
Open
€ 0,95
High
€ 0,95
Low
€ 0,92
Volume
6.124.104

Profile

 
Profile
Pharming is an innovative biotechnology company that has the mission to create value for all shareholders through the development of therapeutic products for humans. Pharming's goal is the development and commercialization of therapeutic proteins for difficult to treat or non-treatable diseases, thus helping patients and add value for shareholders. The developed applications can be applied in the case of genetic anomalies or use in resolving tissue damage after surgery. The current focus of Pharming is on product innovation. Future growth of the company is pursued through licensing products, its technology and strategic transactions.
Industry
Biotechnology
Description
Companies in the biotechnology industry are performing research and development activities for the purpose of discovering new drugs and diagnostics. The turnover of these companies comes from sales of these products or the sale of licenses of drugs and diagnostic to other companies.

Key figures (2017)

 
The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings
-6,662
Price to Earnings (3 years)
-14,871
Price to Earnings (5 years)
-20,761
Price to earnings growth
-
Price/cashflow
-6,960
Price/net cashflow
18,419
Price/book value
-
Price to sales
5,944

Ratios for dividend

Dividend yield
-
Pay out
-

Valuation ratios

Market value/PE
-
Market value/turnover
5,944
Enterprise value/turnover
5,612

Return ratios

Return on private equity
-
Return on total equity
-48,11%
Profit margin
-89,22%

Risk ratios

Solvability
-
Solvability
-
Current ratio
1,508
Debt to Equity
-

Value invest ratios

Grahams Number
-
Grahams Value
-
Grahams Product
-
Grahams Product (3 years)
-

2017

 

Profit and loss

Net profit (x 1 mln)
€ -79,96
Turnover (x 1 mln)
€ 89,62
Cashflow(x 1 mln)
€ -76,54
Net cashflow(x 1 mln)
€ 28,92

Balance

Private equity (x 1 mln)
-
Foreign equity (x 1 mln)
-
Current assets (x 1 mln)
€ 88,25
Current liabilities (x 1 mln)
€ 58,53
Working capital (x 1 mln)
€ 29,72
Balance total (x 1 mln)
€ 166,19

Share

Outstanding shares (x 1 mln)
579,010
Price year-end
€ 1,13
Dividend per share
-
Earnings per share
€ -0,14
Cashflow per share
€ -0,13
Net cashflow per share
€ 0,05
Book value per share
-
Stockmarket value (x 1 mln)
€ 655,44

History

 
Year
2017
2016
2015
2014
2013
Net profit (x 1 mln)
€ -79,96
€ -17,54
€ -9,96
€ -5,77
€ -15,06
Turnover (x 1 mln)
€ 89,62
€ 16,21
€ 10,98
€ 21,29
€ 6,95
Price year-end
€ 1,13
€ 0,22
€ 0,28
€ 0,39
€ 0,14
Year high
€ 1,38
€ 0,32
€ 0,41
€ 0,73
€ 0,18
Year low
€ 0,22
€ 0,15
€ 0,24
€ 0,14
€ 0,01
Outstanding shares (x 1 mln)
579,010
407,687
407,687
407,687
213,008
Price to Earnings
-8,197
-5,044
-11,543
-27,485
-2,023
Earnings per share
€ -0,14
€ -0,04
€ -0,02
€ -0,01
€ -0,07
Dividends
-
-
-
-
-
Dividend yield
-
-
-
-
-
Pay out
-
-
-
-
-
Private equity (x 1 mln)
-
€ 27,47
€ 23,84
€ 29,84
€ 5,01
PE per share
-
€ 0,07
€ 0,06
€ 0,07
€ 0,02
Balance total (x 1 mln)
€ 166,19
€ 126,78
€ 57,68
€ 55,72
€ 31,41
Stockmarket value (x 1 mln)
€ 655,44
€ 88,47
€ 114,97
€ 158,59
€ 30,46

Company analysis

 

Analysis of profit indicators

Average profit per share (10 years)
€ -0,21
Standard deviation average profit
€ 0,14 (-67,25%)
Average annual growth rate
-12,54%
Compound annual growth percentage
5,12%
© 2009 Skuzet. All Rights Reserved.